1. Scrip
  2. >>Business

Ex-Eylea Leader Launches Biotech Targeting Untapped Eye Market

Complement Therapeutics Exits Stealth Mode

 
• By Andrew McConaghie

Former Bayer executive Rafiq Hasan believes the start-up’s gene therapy candidate can open up treatment to millions of patients with dry AMD and geographic atrophy.

Older eye
There are up to five million people with geographic atrophy worldwide. • Source: Alamy

New biotech company Complement Therapeutics has been launched with big ambitions to develop a gene therapy for millions of patients who suffer from the eye condition geographic atrophy (GA), led by a CEO who had a hand in building the two biggest ophthalmology blockbusters.

The UK company has emerged from stealth mode with a relatively modest €5m in seed funding from European venture capital firms Forbion and BioGeneration Ventures and CEO Rafiq Hasan told Scrip the firm is now focused on achieving an “ambitious” target for a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.